34 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
and gender Slight imbalance in delta below MPH, BMI, and bone age delay KEY: SDS = Standard deviation score MPH = Mid-parental height (Child’s target
8-K
EX-99.2
LUMO
Lumos Pharma Inc
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
for 3.2 mg subjects 24 Patient Gender Age (months) Dose (mg/kg) Height (SDS) Clonidine test (GH ng/mL) PEM test (GH ng/mL) time 0 peak peak 801-101 F
8-K/A
5ybnwn 6jw6c4yb1oq
1 Jun 20
Other Events
12:00am
8-K
EX-10.2
ingubir
18 Mar 20
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
4:37pm
DEFR14A
qrwa75
13 Feb 20
Revised proxy
4:37pm
DEFM14A
upxgl60 qr17i0
10 Feb 20
Proxy related to merger
8:30am
PRER14A
zccozdfmt3pawo
9 Jan 20
Preliminary revised proxy
8:02am
PREM14A
s04p flakbrrdi
20 Nov 19
Preliminary proxy related to merger
6:38am
DEFA14A
EX-2.1
elroqyzqcull 9ri08
30 Sep 19
Additional proxy soliciting materials
12:00am
8-K
EX-2.2
akswlbhu6wv3
30 Sep 19
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
hejs319
30 Sep 19
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.2
wgdye2r
30 Sep 19
Additional proxy soliciting materials
12:00am